The good news about Truvada/PrEP continues this week.
Researchers from UCLA, publishing in the Oxford Journal say that PrEP, as far as they can tell for short- to medium-term use, is as safe as over-the-counter aspirin for human consumption, and in terms of possible side effects.
Researchers from the University of California Los Angeles compared five major studies on PrEP for HIV infection with two major studies on aspirin Safety. Each medication was given a score based on how numbers needed to harm (NNH), or cause a reported side effect.
The report concluded that the use of Truvada as PrEP was favorable to Aspirin in terms of safety, but that more studies on long-term use were needed. Still, those users who have engaged in short or medium term PrEP should be reassured of the drug’s safety.
Per the Oxford Journal piece, “While long-term studies are needed, providers should feel reassured about the safety of short- and medium-term PrEP.”
This news comes a few months after a three-year study of gay men taking PrEP in San Francisco that showed zero new HIV infections, and it comes after a terrific op-ed piece in adult industry publication AVN that explains in detail why the LA-based AIDS Healthcare Foundation has been so bizarrely anti-PrEP it all comes down to money, of course, and how much less they’ll take in at their HIV testing centers and clinics if everyone gets on PrEP. Also, executive director Michael Weinstein really hates the porn industry, for whatever reason.